

Special Issue

Hepatocellular Carcinoma: From Molecular Mechanisms to Novel Therapeutic Approaches

Message from the Guest Editor

This Special Issue, "Hepatocellular Carcinoma: From Basic Research to Novel Therapeutic Approaches," will focus on molecular findings, pathology, biomarkers, diagnostic imaging, clinical features, and novel therapeutic approaches relating to hepatocellular carcinoma (HCC). HCC is the fourth leading cause of cancer-related death worldwide. It is a highly heterogeneous tumor at the molecular and pathological levels, and its incidence is increasing in Western countries. In the past decade, novel molecular findings, pathogenic mechanisms, and therapeutic targets have improved our understanding of HCC. Despite advances in many areas, the molecular pathogenesis of HCC has not been fully elucidated. The accurate diagnosis of HCC and therapeutic strategies remain challenging. This Special Issue is open to basic and clinical research on HCC, as well as multidisciplinary approaches, and will cover original articles and reviews on the following topics: hepatocellular carcinoma, primary liver cancer, molecular biology, carcinogenesis, precancerous conditions, subtypes, biomarkers, diagnostic imaging, and novel therapeutic approaches.

Guest Editor

Prof. Dr. Joon Hyuk Choi

Department of Pathology, Yeungnam University College of Medicine,
Daegu, Republic of Korea

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/135368

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).